Antibodies to the Human Papillomavirus 16 and 18 E7 Proteins: A Possible Diagnostic Marker for Cervical Cancer

  • M. Müller
  • I. Jochmus
  • C. Bleul
  • K. V. Shah
  • R. K. Viscidi
  • L. Gissmann
Conference paper

Abstract

Human papillomavirus (HPV) types 16 and 18 belong to a heterogeneous group of epitheliotropic viruses which induce benign proliferations of the skin or mucosa (for review, see de Villiers 1989). During the past few years it became evident that they are associated with malignant tumors of the anogenital tract, particularly of the uterine cervix (for review, see zur Hausen 1989). Besides the demonstration of the transforming activity of the early viral genes E6 and E7 in vitro, the strongest evidence for a causative role of HPV 16 and HPV 18 in tumor development arose from the frequent detection of their genomes in tumor biopsies as well as in cell lines derived therefrom. After the tumorigenic properties of HPV 16 and 18 had become apparent, it was assumed that detection of the virus in healthy individuals could be of diagnostic value for determining the risk of developing cancer of the uterine cervix. Subsequent studies, however, demonstrated that the viruses quite frequently persist in clinically normal cervical epithelium, and it is not yet clear how frequently a latent infection may lead to a clinically overt lesion and finally to a malignant tumor.

Keywords

Cervical Cancer Uterine Cervix Human Seron Cervical Cancer Patient Normal Cervical Epithelium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bleui C, Müller M, Frank R, Gausepohl H, Koldovsky U, Mgaya HN, Luande J, Pawlita M, ter Meulen J, Viscidi R, Gissmann L (1991) Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. J Clin Microbiol 29 (in press)Google Scholar
  2. De Villiers E-M (1989) Heterogeneity of the human papillomavirus group. J Virol 63: 4898–4903PubMedGoogle Scholar
  3. Geysen HM, Meloen RH, Barteling SJ (1984) Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proc Natl Acad Sci USA 81: 3998–4002PubMedCrossRefGoogle Scholar
  4. Ikenberg H (1991) Human papillomavirus DNA in invasive genital papillomas. In: Gros G, Jablonska S, Pfister H, Stegner H-E (eds) Genital papillomavirus infections. Springer, Berlin Heidelberg New York, pp 87–112Google Scholar
  5. Jochmus-Kudielka I (1991) Untersuchung der humoralen Immunantwort gegen frühe Proteine der menschlichen Papillomviren (HPV) Typ 1, 11, 16 und 18. PhD thesis, University of MunichGoogle Scholar
  6. Jochmus-Kudielka I, Gissmann L (1990) Expression of human papillomavirus type 16 proteins in Escherichia coli and their use as antigens in serological tests. In: Alitalo KK, Hutala ML, Knowles J, Vaheri A (eds) Recombinant systems in protein expression. Elsevier, Amsterdam, pp 87–93Google Scholar
  7. Jochmus-Kudielka I, Schneider A, Braun R, Kimmig R, Koldovsky U, Schneweis K-E, Seedorf K, Gissmann L (1989) Antibodies against human papillomavirus type 16 early proteins in human sera: anti E7 reactivity correlates with cervical cancer. JNCI 81: 1698–1704PubMedGoogle Scholar
  8. Krchnak V, Vagner J, Suchnkova A, Krzmar M, Ritterova L, Vonka V (1990) Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J Gen Virol 71: 2719–2724PubMedCrossRefGoogle Scholar
  9. Mann VM, Loo de Lao S, Brenes M, Brinton LA, Rawls JA, Green M, Reeves WC, Rawls WE (1990) Occurrence of IgA and IgG antibodies to select (sic) peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Res 50: 7815–7819Google Scholar
  10. Müller M, Gausepohl H, de Martynoff G, Frank R, Brasseur R, Gissmann L (1990) Identification of seroreactive regions of the human papillomavirus type 16 proteins E4, E6, E7 and Ll. J Gen Virol 71: 2709–2717PubMedCrossRefGoogle Scholar
  11. Müller M, Viscidi RP, Sun Y, Guerrero E, Hill PM, Shah F, Bosch FX, Munoz N, Gissmann L, Shah KV (1991) Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16associated invasive cervical cancer. Virology (in press)Google Scholar
  12. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R (1989) The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63: 4417–4421PubMedGoogle Scholar
  13. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, Stremlau A, zur Hausen H (1985) Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314: 111–114PubMedCrossRefGoogle Scholar
  14. Smith GP (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228: 1315–1317PubMedCrossRefGoogle Scholar
  15. Yee C, Krishnan-Hewlett I, Baker CC, Schlegel R, Howley PM (1985) Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines. Am J Pathol 119: 361–366PubMedGoogle Scholar
  16. Zur Hausen H (1989) Papillomaviruses as carcinomaviruses. In: Klein G (ed) Advances in viral oncology, vol 8. Raven, New York, pp 1–26Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • M. Müller
  • I. Jochmus
  • C. Bleul
  • K. V. Shah
  • R. K. Viscidi
  • L. Gissmann

There are no affiliations available

Personalised recommendations